SION - Sionna Therapeutics, Inc.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON SIONNA THERAPEUTICS, INC. (SION), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Hap.
Law Offices of Howard G. Smith announces an investigation on behalf of Sionna Therapeutics, Inc. (âSionnaâ or the âCompanyâ) (NASDAQ: [url="]SION[/url])
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SIONNA THERAPEUTICS, INC. (SION), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On August 10, 2026, Sionna reported topline data from.
SAN DIEGO--(BUSINESS WIRE)---- $SION #Health--Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders. Why Are We Investigating Sionna Therapeutics? On Monday, August 10, 2026, Sionna Therapeutics stock plunged 92% to close at $4.51 after the Company reported disappointing results from its Phase 2a proof-of-concept study of SION-719 in.
Sionna Therapeutics shares plunged roughly 90% in a single trading session after the SION-719 Phase 2a readout -- erasing most of the Company's equity value. Levi & Korsinsky is investigating potential securities law violations on behalf of SION investors. Sionna Therapeutics shares plunged roughly 90% in a single trading session after the SION-719 Phase 2a readout -- erasing most of the Company's equity value. Levi & Korsinsky is investigating potential securities law violations on behalf of SION investors.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.
SAN DIEGO, Aug. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline
NEW YORK--(BUSINESS WIRE)--Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline of approximately $40 per share from the stock's recent trading levels. If you held SION shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The impact on shareho.
Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential securities law violations, and SION investors who lost money have legal rights worth reviewing now.
SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law
SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
Sionna Therapeutics told investors its SION-719 program was on track; the Phase 2a Trial Failed Key Endpoint and stock lost roughly 90% of its value. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Sionna Therapeutics (NASDAQ: SION) shareholders watched roughly 90% of their investment disappear after the Company reported that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction and that the candidate would not advance as an add-on therapy.
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). Click here to join the investigation.
Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.
Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ:SION) announced topline clinical trial results from two nucleotide binding domain 1 (NBD1) stabilizer candidate programs targeting cystic fibrosis (CF).
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript